#USA #Cardiff-by-the-Sea #Field Medical #FieldForce #Pulsed Field Ablation

Field Medical Secures $35 Million in Series B Funding

Field Medical, Inc., a dynamic clinical-stage company, is making waves in the cardiac ablation sector with its next-generation pulsed field ablation (PFA) technology. On July 1, 2025, the firm announced the successful closing of an oversubscribed Series B funding round, raising $35 million. This round was co-led by BioStar Capital and Cue Growth, with significant contributions from existing strategic investors. The new capital positions Field Medical to advance its pivotal clinical trials and enhance its FieldForce™ platform aimed at treating ventricular tachycardia (VT).

Accelerating Clinical Development

The received funding will primarily support the initiation of the vital VERITAS trial, focusing on the FieldForce™ system that has been designed for transmural lesion creation. This innovative approach is expected to redefine VT ablation, addressing a gap in electrical cardiology where current solutions often fall short. Dr. Steven Mickelsen, founder and CEO of Field Medical, stated, "Ventricular tachycardia remains among the least penetrated segments in electrophysiology, yet there is a profound clinical need for effective tools. Our next-gen therapy is designed for speed, precision, and meaningful clinical advancement."

Impressive pilot data showcased during the Heart Rhythm Society 2025 meeting further fueled investor interest, reflecting the company’s potential in addressing unmet needs in complex arrhythmias. With the latest funding, Field Medical has successfully raised $75 million to date, solidifying its leadership in the innovation of PFA technology used in treating arrhythmias.

Leadership Updates to Propel Growth

To accompany its rapid growth trajectory, Field Medical announced significant updates to its board of directors. Some key members include :

• - Dr. Steven Mickelsen: Founder and CEO, an acknowledged electrophysiologist and serial entrepreneur.
• - Mark Wisniewski: CFO of Enterra Medical, now acting as Board Chairman, bringing deep medical device experience.
• - Marlou Janssen: Executive and board member with decades of leadership experience in medical technology.
• - Alexei Mlodinow: A surgeon and venture capitalist with a record of innovating within medical technology.
• - Ben Cannon: Founding partner at Cue Growth with extensive operational experience in growing companies.

This bolstered team reflects the determination and readiness of Field Medical as it gears up for crucial trials and aims to change the landscape for high-risk patients suffering from VT.

Field Medical's Vision and Innovation

Founded in 2022, Field Medical focuses on developing cutting-edge pulsed field ablation technologies to treat complex cardiac arrhythmias. The company’s FieldForce™ Ablation System combines innovative catheter design with advanced technology, enhancing the speed and accuracy of ablation procedures. The system has already garnered the FDA's Designation of Innovative Device and was selected for the FDA TAP Pilot Program for VT indications, which underscores its promising potential in the medical field.

For more information on their groundbreaking technologies and clinical approaches, visit Field Medical's official website. The FieldForce™ system is currently in research phases and usage is limited under federal law for investigational purposes.

Field Medical is not just a company; it's a beacon of hope for the future of cardiac care. As they continue to push boundaries within electrophysiology, the medical community eagerly anticipates the outcomes of their pivotal trials that promise to reshape patient care in arrhythmia treatment.